- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.
Critère d'inclusion
- Germ Cell Tumor